RT Journal Article
SR Electronic
T1 X-Chromosome-wide association study for Alzheimer’s disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.02.24306739
DO 10.1101/2024.05.02.24306739
A1 Le Borgne, Julie
A1 Gomez, Lissette
A1 Heikkinen, Sami
A1 Amin, Najaf
A1 Ahmad, Shahzad
A1 Choi, Seung Hoan
A1 Bis, Joshua
A1 Grenier-Boley, Benjamin
A1 Rodriguez, Omar Garcia
A1 Kleineidam, Luca
A1 Young, Juan
A1 Tripathi, Kumar Parijat
A1 Wang, Lily
A1 Varma, Achintya
A1 van der Lee, Sven
A1 Damotte, Vincent
A1 de Rojas, Itziar
A1 Palmal, Sagnik
A1 Giedraitis, Vilmantas
A1 Ghidoni, Roberta
A1 Fernandez, Victoria
A1 Kehoe, Patrick Gavin
A1 Frikke-Schmidt, Ruth
A1 Tsolaki, Magda
A1 Sánchez-Juan, Pascual
A1 Sleegers, Kristel
A1 Ingelsson, Martin
A1 Haines, Jonathan
A1 Farrer, Lindsay
A1 Mayeux, Richard
A1 Wang, Li-San
A1 Sims, Rebecca
A1 DeStefano, Anita
A1 Schellenberg, Gerard D.
A1 Seshadri, Sudha
A1 Amouyel, Philippe
A1 Williams, Julie
A1 van der Flier, Wiesje
A1 Ramirez, Alfredo
A1 Pericak-Vance, Margaret
A1 Andreassen, Ole
A1 Van Duijn, Cornelia
A1 Hiltunen, Mikko
A1 Ruiz, Agustín
A1 Dupuis, Josée
A1 Martin, Eden
A1 Lambert, Jean-Charles
A1 Kunkle, Brian
A1 Bellenguez, Céline
YR 2024
UL http://medrxiv.org/content/early/2024/05/03/2024.05.02.24306739.abstract
AB Due to methodological reasons, the X-chromosome has not been featured in the major genome-wide association studies on Alzheimer’s Disease (AD). To finally address this and better characterize the genetic landscape of AD, we performed an in-depth X-Chromosome-Wide Association Study (XWAS) in 115,841 AD cases or AD proxy cases, including 52,214 clinically-diagnosed AD cases, and 613,671 controls. We considered three approaches to account for the different X-chromosome inactivation (XCI) states in females, i.e. random XCI, skewed XCI, and escape XCI. We did not detect any genome-wide significant signals (P ≤ 5 × 10−8) but identified four X-chromosome-wide significant loci (P ≤ 1.7 × 10−6). Two signals locate in the FRMPD4 and DMD genes, while the two others are more than 300 kb away from the closest protein coding genes NLGN4X and GRIA3. Overall, this XWAS found no common genetic risk factors for AD on the non-pseudoautosomal region of the X-chromosome, but it identified suggestive signals warranting further investigations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementEADB: This study was supported by grants from the Fondation pour la Recherche sur Alzheimer (convention 2022-A-01 and cluster grant), and the JPco-fuND-2 ‘Multinational research projects on Personalized Medicine for Neurodegenerative Diseases’ PREADAPT project (ANR-19-JPW2-0004). We thank the many study participants, researchers and staff for collecting and contributing to the data, the high-performance computing service at the University of Lille and the staff at CEA-CNRGH for their help with sample preparation and genotyping and excellent technical assistance. We thank Antonio Pardinas for his help. We thank the Netherlands Brain Bank. This research was conducted using the UKBB resource (application number 61054). This work was funded by a grant (EADB) from the EU Joint Programme - Neurodegenerative Disease Research. Inserm UMR1167 is also funded by the Inserm, Institut Pasteur de Lille, Lille Métropole Communauté Urbaine and French government’s LABEX DISTALZ program (Development of Innovative Strategies for a Transdisciplinary Approach to ALZheimer’s disease). This work was also supported by the Research Council of Finland grants 338182 and 334802, the Sigrid Jusélius Foundation, and the Strategic Neuroscience Funding of the University of Eastern Finland. Full consortium acknowledgements and funding are in the Supplementary Note.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written informed consent was obtained from study participants or, for those with substantial cognitive impairment, from a caregiver, legal guardian or other proxy. Study protocols for all cohorts were reviewed and approved by the appropriate institutional review boards. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes